16 Oct 09
Biopta has launched CardioForesightTM; the first available human cardiovascular safety package, which allows GLP or non-GLP assessment of peripheral vascular resistance, cardiac contractility, electrophysiology and coronary artery blood flow, entirely through the use of human cells and tissues.
Download an information sheet on the CardioForesight package from the following page:
www.biopta.com/resource_library/resource_library.aspx